First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers

First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers

ApTOLL is an aptamer that antagonizes Toll-like receptor 4 and improves functional outcomes in models of ischemic stroke and myocardial infarction. The aim of this study was to characterize the safety and pharmacokinetics of ApTOLL in healthy volunteers. A first-in-human dose-ascending, randomized,...

Full description

Bibliographic Details
Main Authors: Macarena Hernández-Jiménez, Samuel Martín-Vílchez, Dolores Ochoa, Gina Mejía-Abril, Manuel Román, Paola Camargo-Mamani, Sergio Luquero-Bueno, Bernd Jilma, María A. Moro, Gerónimo Fernández, David Piñeiro, Marc Ribó, Víctor M. González, Ignacio Lizasoain, Francisco Abad-Santos
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
MT: oligonucleotides
MT: therapies and applications
aptamer
TLR4
inflammation
antagonist
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253122000543

Internet

http://www.sciencedirect.com/science/article/pii/S2162253122000543

Similar Items